

04-27-01

Please type a plus sign (+) inside this box → 

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37C F.R. §1 53(b))

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)	6. <input type="checkbox"/> Microfiche Computer Program (Appendix)
2. <input checked="" type="checkbox"/> Specification [Total Pages 30]	7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- Descriptive title of the Invention	
- Cross References to Related Applications	
- Statement Regarding Fed sponsored R&D	
- Reference in Microfiche Appendix	
- Background of the Invention	
- Brief Summary of the Invention	
- Brief Description of the Drawings (if filed)	
- Detailed Description	
- Claim(s)	
- Abstract of the Disclosure	
3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 11.3)[Total sheets 13]	8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
4. <input checked="" type="checkbox"/> Oath or Declaration [Total pages 3]	9. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement <input type="checkbox"/> Power of Attorney (when there is an assignee)
a. <input type="checkbox"/> Newly executed (original or copy)	
b. <input type="checkbox"/> Copy from a prior application (37 CFR §1.63(d)) (for continuation/divisional with Box 17 completed) [Note Box 5 below]	
i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b).	
5. <input type="checkbox"/> Incorporation By Reference (useable if Box 4b is checked)	10. <input type="checkbox"/> English Translation Document (if applicable)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	
12. <input checked="" type="checkbox"/> Preliminary Amendment	
13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)	
14. <input type="checkbox"/> *Small Entity <input type="checkbox"/> Statement filed in prior application, Statement(s) Status still proper and desired (PTO/SB/09-12)	
15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)	
16. <input type="checkbox"/> Other:	


\*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment

Continuation  Divisional  Continuation-in-part (CIP) of prior application No: /

Prior application information: Examiner \_\_\_\_\_ Group/Art Unit: \_\_\_\_\_

## 18. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label		(Insert Customer No. or Attach bar code label here)			<input type="checkbox"/> or <input checked="" type="checkbox"/> Correspondence address below
Name	Paul H. Ginsburg				
Address	Pfizer Inc				
Address	235 East 42nd Street, 20th Floor				
City	New York	State	New York	Zip Code	10017-5755
Country	United States Of America	Telephone	(212)573-2369	Fax	(212)573-1939
NAME (Print/type)	SETH H. JACOBS		Registration No. (Attorney/Agent)	32,140	
Signature			Date	04-26-01	

**FEE TRANSMITTAL**

Patent fees are subject to annual revision on October 1.  
These are the fees effective October 1, 1997

Small Entity payments **must** be supported by a small entity statement,  
otherwise large entity fees must be paid. See Forms PTO/SB/09-12

See 37 C.F.R. §§ 1.27 and 1.28.

**Total Amount of Payment** **(\$)** **710.00**

Complete if Known

Application Number	Not yet assigned
Filing Date	Concurrent herewith
First Named Inventor	L. Buckbinder
Examiner Name	Not yet assigned
Group/Art Unit	Not yet assigned
Attorney Docket No.	PC10873B

**METHOD OF PAYMENT** (check one)

The commissioner is hereby authorized to charge  
Indicated fees and credit any over payments to:

Deposit Account Number **Pfizer Inc**

Deposit Account Name **16-1445**

Charge Any Additional Fee Required Under  
37 C.F.R. §§ 1.16 and 1.17.  Charge the Issue Fee Set in  
37 C.F.R. § 1.18 at the Mailing  
of the Notice of Allowance

**Payment Enclosed:**

Check  Money Order  Other

**FEE CALCULATION** (continued)**3. ADDITIONAL FEES**

Large Entity	Small Entity	Fee Description				Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)			
105	130	205	65	Surcharge – late fee or oath		
127	50	227	25	Surcharge—late provisional filing fee or cover sheet		
139	130	139	130	Non-English specification		
147	2,520	147	2,520	For filing a request for reexamination		
112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		
115	110	215	55	Extension for reply within first month		
116	390	216	195	Extension for reply within second month		
117	890	217	445	Extension for reply within third month		
118	1,390	218	695	Extension for reply within fourth month		
128	1,890	228	945	Extension for reply within fifth month		
119	310	219	155	Notice of Appeal		
120	310	220	155	Filing a brief in support of an appeal		
121	270	221	135	Request for oral hearing		
138	1,510	138	1,510	Petition to institute a public use proceeding		
140	110	240	55	Petition to revive - unavoidable		
141	1,240	241	620	Petition to revive - unintentional		
142	1,240	242	620	Utility issue fee (or reissue)		
143	440	243	220	Design issue fee		
144	600	244	300	Plant issue fee		
122	130	122	130	Petitions to the Commissioner		
123	50	123	50	Petitions related to provisional applications		
126	240	126	240	Submission of Information Disclosure Statement		
581	40	581	40	Recording each patent assignment per property (times number of properties)		
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))		
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))		
Other Fee (specify)						
Other Fee (specify)						

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3) (\$)**

**SUBMITTED BY**

Type or Printed Name	SETH H. JACOBS	Complete (if Applicable)
Signature		Reg. Number <b>32,140</b> Deposit Account User ID

CERTIFICATE OF MAILING EXPRESS MAIL

PFIZER DOCKET NO: PC10873B

APPLICATION NUMBER: NOT YET ASSIGNED

TITLE: ADAMTS POLYPEPTIDES, NUCLEIC ACIDS ENCODING THEM, AND USES THEREOF


APPLICANT: Leonard Buckbinder, *et al.*

"Express Mail" mailing label number EL446402267US

Date of Deposit: April 26, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Michelle Dungee

  
(Signature of person mailing paper or fee)

Pfizer, Inc  
Patent Department, 20th Floor  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 733-3189